Source: Annual Congress 2002 - High altitude and hypoxia
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. A. Aldashev, B. B. Kalmyrzaev, T. Y. Mirzapoyazova, E. V. Kim, L. B. Mamanova, A. S. Sarybaev, A. S. Sydykov, B. K. Kojonazarov, M. R. Wilkins, N. W. Morrell (Bishkek, Kyrgyzstan; London, United Kingdom). The β-2 adrenoreceptor GLN27GLU gene polymorphism and high-altitude pulmonary hypertension in KYRGYZ highlanders. Eur Respir J 2002; 20: Suppl. 38, 691

Member's Comments

No comment yet.

Related content which might interest you: Gene polymorphism and development of high-altitude pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 94s Year: 2004 Association of Met235Thr polymorphism of AGT gene with high altitude pulmonary arterial hypertension in Kyrgyz highlanders Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 S/L polymorphism of serotonin transporter gene and development of high altitude pulmonary hypertension in Kyrgyz highlanders Source: Eur Respir J 2005; 26: Suppl. 49, 351s Year: 2005 Angiotensin-converting enzyme gene polymorphism as a risk factor of high-altitude pulmonary hypertension in Kyrgyz highlanders Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001 The b -2 adrenoreceptor Gln27Glu gene polymorphism could play role in high-altitude pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Measurement of haplotype analysis of ACE gene and the development of high altitude pulmonary hypertension in Kyrgyz highlanders Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Effects of sildenafil on secondary pulmonary hypertension in highlanders with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 73s Year: 2007 Calcium channel activity in lowlanders and in highlanders with pulmonary hypertension due to chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 99s Year: 2002 Endothelin and high altitude pulmonary hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Association of the 3A/4A (134delA) and Lys198Asn polymorphisms of the endothelin-1 gene with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Pulmonary hemodynamics in highlanders with high altitude pulmonary hypertension in 1 year after finishing of sildenafil treatment Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Effects of fasudil in patients with high-altitude pulmonary hypertension Source: Eur Respir J 2012; 39: 496-498 Year: 2012 Common genetic basis for pulmonary arterial hypertension and high altitude pulmonary edema Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 VNTR polymorphism NOS3 gene among chronic obstructive pulmonary disease patients Source: Eur Respir J 2003; 22: Suppl. 45, 392s Year: 2003 The gln27 beta adrenoceptor polymorphism is associated with bronchodilator reversibility in subjects with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 96s Year: 2002 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Fibrinogen AaThr312Ala polymorphism predisposes to chronic thromboembolic pulmonary hypertension Source: Annual Congress 2007 - Acute and chronic pulmonary embolism Year: 2007 Relationship of the polymorphism Lys198Asn endothelin-1 gene with COPD and coronary heart disease. Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020